Relay Medical Enters Binding LOI For Global Rights To COVID-19 Tests

Relay Medical (CSE: RELA) has entered into an arrangement to exclusively sell and distribute two separate rapid diagnostic tests for COVID-19. Announced after the bell yesterday, the arrangement is currently classified as a binding letter of intent, which was entered into with Proprietary Innovation Labs.

The arrangement will see Relay’s medical diagnostic subsidiary, HemoPalm Corp, acquire the exclusive global rights (excluding China) to sell and distribute both an antigen and an antibody test kit for COVID-19. The antigen test is notably a lateral flow rapid diagnostic test, akin to a rapid pregnancy test. Both tests are CE approved, enabling the sale and distribution within Europe and other jurisdictions.

The tests are said to be ideal for point of care testing, with results available in as little as ten minutes. The manufacturer is notably capable of producing over 25 million test kits per month, enabling significant sales opportunities should Relay develop the required sales channels.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

Further, the company is considering submitting to both Health Canada and the US Food and Drug Administration to enable domestic approval of the device as an approved COVID-19 test. Currently, the CE designation enablres the sale of the test kits in 22 countries within the European Union.

In terms of the technical data, the antigen test, which tests for active infections, has a clinical sensitivity of 95.0% and a clinical specificity of 99.6%. The antibody test, which measures immune responses in people suspected of carrying the virus, comparatively has a clinical sensitivity of 93.3% and a clinical specificity of 99.0%.

With respect to terms, the company intends to enter a definitive agreement within 45 days. Currently, it is outlined that an exclusive identifiable brand will be mutually agreed to by both parties, while profits will be shared from the sale of products. 60% of the profits from a sale will be provided to the party sourcing the purchaser, while 40% goes to the other party. Relay also issued 400,000 common shares in connection with the agreement.

Relay Medical last traded at $0.21 on the CSE.


FULL DISCLOSURE: Relay Medical Corp is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Relay Medical Corp on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Goliath Extends Golden Gate Lode 130 Metres With 13.45 g/t Gold Equivalent Over 4.85 Metres

Questcorp Begins 600 Metre Phase 2B Drill Program at La Union

Related News

United States Breaks 4 Day Trend Of 1,000 COVID-19 Deaths A Day

The United States finally broke below the 1,000 deaths per day figure on Saturday, following...

Sunday, July 26, 2020, 03:45:00 PM

Retail Landlords Begin Issuing Default Notices to Tenants

It appears the economic implication stemming from the coronavirus pandemic keep mounting. As retailers were...

Tuesday, May 26, 2020, 05:03:00 PM

US Voters Becoming Increasingly Pessimistic On Economic Recovery, Success of Coronavirus Mitigation Measures

As the coronavirus pandemic continues to rage on in the US, American voters are growing...

Wednesday, July 8, 2020, 09:00:00 PM

US With Another 3.0M Jobless Claims; 36M Over Last 8 Weeks.

This morning the Department of Labor released initial jobless claims data for the week ended...

Thursday, May 14, 2020, 09:21:57 AM

Coronaviral! Market Movers Takes On The Low-Float Pandemic Pops

There’s no panic like a pandemic. Equities markets of all kinds took another tumble Friday...

Saturday, February 29, 2020, 11:37:57 AM